Recent studies have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopaminergic neurotransmission. While GIP agonists are commonly employed for treating type 2 T2DM, their unexpected effects on reinforcement circuits, specifically mediated by dopamine systems, are ga… Read More